The company's lead candidate drug is an oral drug that blocks DQ8 on specific immune cells to starve the autoimmune process in type 1 diabetes (T1D), with the goal of preserving pancreatic beta-cell function and maintaining normal insulin production in at-risk and early-stage patients. IM Therapeutics is leveraging its HLA platform to expand its pipeline beyond T1D, including drug development for Celiac disease and other potential autoimmune diseases. They use rational drug design and bioassays to develop targeted therapeutic candidates, providing patients and the medical community access to a broad pipeline of drugs against HLA targets in autoimmune disorders. Founded in 2015 and headquartered in Aurora, Colorado, IM Therapeutics is building an HLA-directed platform for new therapies.